Navigating Renal Autologous Cell Therapy (REACT) as a Potential Advanced Therapy for Late-Stage Diabetic Kidney Disease

Time: 1:00 pm
day: Track 1 - Day 2 AM


  • Exploring promising early efficacy and safety results restoring and stabilizing renal function and injury in clinical trials with REACT
  • Individuals with Stage 3 and 4 type 2 diabetic CKD at high risk for ESRD may represent an optimal patient population
  • REACT has received expedited pathway designation from FDA and endorsement to launch a global Phase III clinical trial